Pfizer will earn over $13 billion this year from Lipitor and it makes perfect sense for them to fund a study that would broaden the indications for their blockbuster drug. After all, they surely could use a few more billion dollars.
However, it is really questionable whether Lipitor really does decrease the risk of strokes. You need to read between the lines of this one to uncover what the study really says, which is not quite what Pfizer claims it says: http://www.mercola.com/2006/aug/24/the_next_statin_scam_preventing_strokes.htm.
Comments